Newsfeeds - Spark Newswire

2 minute read

Provention Bio Resubmitting Biologics License Application For Delay Of Clinical Type 1 Diabetes In At-Risk Individuals Following Type B Meeting With The FDA

Today, 11:13 PM

Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced its intent to resubmit the teplizumab Biologics

PRVB

1 minute read

Provention Bio Announces Initiation Of Phase 2a PREVAIL-2 Study Of PRV-3279 (CD32B × CD79 Bispecific DART Molecule) In Systemic Lupus Erythematosus

By Bill Haddad

Today, 11:13 PM

- PRV-3279 is Designed to Intercept B-Cell Mediated Autoimmune Diseases - - Potential to be a Non-Depleting B-Cell Modulating Therapeutic for the Treatment of SLE - RED BANK, N.J., Jan. 20, 2022 /PRNewswire/ --

PRVB

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 11:13 PM

During Friday's session, 445 companies made new 52-week lows.

AAOI

32 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 11:13 PM

On Thursday, 615 stocks hit new 52-week lows.

AAOI

5 minute read

61 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:13 PM

Gainers

AEVA

1 minute read

Provention Bio Shares Gain On Teplizumab Regulatory Update For Type 1 Diabetes

By Vandana Singh

Today, 11:13 PM

The FDA has approved Provention Bio Inc's (NASDAQ: PRVB) proceeding to

PRVB

3 minute read

40 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 11:13 PM

Gainers

AHI

1 minute read

Provention Bio Q3 EPS $(0.43) Beats $(0.51) Estimate

By Benzinga Newsdesk

Today, 11:13 PM

Provention Bio (NASDAQ:PRVB) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.51) by 15.69 percent. This is a 23.21 percent increase over losses of $(0.56) per share from

PRVB

32 minute read

Earnings Scheduled For November 4, 2021

By Benzinga Insights

Today, 11:13 PM

Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

AAOI

7 minute read

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline

Today, 11:13 PM

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT